- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nykode Therapeutics ASA (NYKD)
Nykode Therapeutics ASA stock price live, this page displays OL NYKD stock exchange data. View the NYKD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Nykode Therapeutics ASA real time stock price chart below.
What Is the Nykode Therapeutics ASA Stock Price Today?
The Nykode Therapeutics ASA stock price today is 3.05.
What Is the Stock Symbol for Nykode Therapeutics ASA?
The stock symbol for Nykode Therapeutics ASA is "NYKD."
What Stock Exchange Does Nykode Therapeutics ASA Trade On?
Nykode Therapeutics ASA is listed and trades on the Oslo stock exchange.
Is Nykode Therapeutics ASA a Good Stock to Buy?
Determining whether Nykode Therapeutics ASA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NYKD quote. (ISIN: NO0010714785)
What Is the Nykode Therapeutics ASA Stock Price Today?
The Nykode Therapeutics ASA stock price today is 3.05.
What Is the Stock Symbol for Nykode Therapeutics ASA?
The stock symbol for Nykode Therapeutics ASA is "NYKD."
What Stock Exchange Does Nykode Therapeutics ASA Trade On?
Nykode Therapeutics ASA is listed and trades on the Oslo stock exchange.
Is Nykode Therapeutics ASA a Good Stock to Buy?
Determining whether Nykode Therapeutics ASA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NYKD quote. (ISIN: NO0010714785)
3.05
-0.07(-2.24%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.05
3.24
52 wk Range
1.44
4.10
NYKD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.053.24
52 wk Range
1.444.10
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NYKD Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
5.00
Upside
+63.93%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 5.00
(+63.93% Upside)
Nykode Therapeutics ASA Earnings Call Summary for Q3/2025
- Nykode Therapeutics reduced Q3 2025 net loss to $3.7M (from $9.7M in Q3 2024) while cutting operating expenses to $6.4M (from $15.6M), despite revenue declining to $118K.
- The company maintains a strong $64M cash position with runway extended to 2028-2029, plus potential $32.5M from a pending tax case.
- Nykode plans a randomized Phase 2 trial for lead asset AviSuva targeting HPV16-driven cancers, with interim data expected by H1 2026.
- VB10.NEO, the company's individualized neoantigen therapy, received a U.S. patent for its NeoSelect platform, positioning it as 'the most attractive, unencumbered INT asset.'
Last Updated: 2025-11-24, 09:56 a/m
Read Full TranscriptEarnings
Latest Release
May 27, 2026
EPS / Forecast
-0.01 / --
Revenue / Forecast
240K / --
Compare NYKD to Peers and Sector
Metrics to compare | NYKD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNYKDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.0x | −4.3x | −0.4x | |
PEG Ratio | −0.18 | 0.01 | 0.00 | |
Price/Book | 1.2x | 0.6x | 2.6x | |
Price / LTM Sales | 186.6x | 0.5x | 3.1x | |
Upside (Analyst Target) | 60.3% | 288.1% | 48.3% | |
Fair Value Upside | Unlock | 3.3% | 6.1% | Unlock |
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Nykode Therapeutics (NYKD) Stock Price Today?
The Nykode Therapeutics stock price today is 3.05 NOK.
What Stock Exchange Does Nykode Therapeutics Trade On?
Nykode Therapeutics is listed and trades on the Oslo Stock Exchange.
What Is the Stock Symbol for Nykode Therapeutics?
The stock symbol for Nykode Therapeutics is "NYKD."
What Is the Nykode Therapeutics Market Cap?
As of today, Nykode Therapeutics market cap is 1.02B NOK.
What Is Nykode Therapeutics's Earnings Per Share (TTM)?
The Nykode Therapeutics EPS (TTM) is -0.05.
From a Technical Analysis Perspective, Is NYKD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Nykode Therapeutics Stock Split?
Nykode Therapeutics has split 1 times.
How Many Employees Does Nykode Therapeutics Have?
Nykode Therapeutics has 57 employees.
What is the current trading status of Nykode Therapeutics (NYKD)?
As of Jul 07, 2026, Nykode Therapeutics (NYKD) is trading at a price of 3.05 NOK, with a previous close of 3.12 NOK. The stock has fluctuated within a day range of 3.05 NOK to 3.24 NOK, while its 52-week range spans from 1.44 NOK to 4.10 NOK.
What Is Nykode Therapeutics (NYKD) Price Target According to Analysts?
The average 12-month price target for Nykode Therapeutics is 5.00 NOK, with a high estimate of 5.5 NOK and a low estimate of 4.5 NOK. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +63.93% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.